% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:1046027,
      author       = {Galldiks, Norbert and Ceccon, Garry and Wollring, Michael
                      Matthias and Stetter, Isabelle and Werner, Jan-Michael and
                      Peplinski, Jana-Marie and Rosen, Jurij and Rosen, Elena K.
                      and Fink, Gereon Rudolf and Langen, Karl-Josef and Lohmann,
                      Philipp},
      title        = {{A}ssessment of 18{F}-{FET} {PET}-based response in
                      patients with gliomas using the {PET} {RANO} 1.0 criteria},
      journal      = {Neuro-oncology advances},
      volume       = {7},
      number       = {1},
      issn         = {2632-2498},
      address      = {Oxford},
      publisher    = {Oxford University Press},
      reportid     = {FZJ-2025-03667},
      pages        = {vdaf198},
      year         = {2025},
      abstract     = {BackgroundWe evaluated the amino acid PET-based response
                      assessment criteria (PET RANO 1.0) for their proficiency in
                      predicting longer survival in patients with gliomas
                      undergoing adjuvant temozolomide chemotherapy.MethodsIn a
                      previous study, 38 patients with newly diagnosed grade 4
                      gliomas according to the World Health Organisation
                      classification underwent O-(2-[18F]fluoroethyl)-L-tyrosine
                      (18F-FET) PET at baseline and after the second cycle of
                      adjuvant temozolomide chemotherapy. The ability of PET
                      parameter changes to predict favorable progression-free and
                      overall survival (PFS, OS) of ≥ 9 and ≥15 months was
                      evaluated. Here, we performed a post-hoc analysis of these
                      PET data to evaluate the PET RANO 1.0 criteria. In addition,
                      the value of the RANO 2.0 criteria for MRI to predict
                      response was evaluated and compared with the PET RANO 1.0
                      criteria.ResultsAccording to the PET RANO 1.0 criteria,
                      patients with Stable Disease (n = 16), Partial Response
                      (n = 9), or Complete Response (n = 0) had a
                      significantly longer OS than patients with Progressive
                      Disease (n = 13) (16.8 vs. 12.0 months; P = 0.016).
                      This difference remained significant in the multivariate
                      survival analysis (HR, 4.185; $95\%$ CI, 1.715-10.530,
                      P = 0.002). In contrast, PFS was not significantly
                      different between the two groups (9.7 vs. 8.1 months;
                      P = 0.147). PET RANO 1.0 criteria could not identify
                      patients with a PFS ≥ 9 months (P = 0.503) or
                      OS ≥ 15 months (P = 0.722). RANO 2.0 criteria for
                      MRI was unable to predict a longer PFS (8.8 vs. 9.8 months;
                      P = 0.565) or OS (16.4 vs. 16.8 months;
                      P = 0.625).ConclusionsOur data suggest that PET RANO 1.0
                      criteria identify survival differences between predefined
                      groups.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1093/noajnl/vdaf198},
      url          = {https://juser.fz-juelich.de/record/1046027},
}